Comparison of the mucosal and systemic antibody responses in Covid-19 recovered patients with one dose of mRNA vaccine and unexposed subjects with three doses of mRNA vaccines

• Published in: Frontiers in immunology Vol. 14; p. 1127401
• Main Authors: Liu, Shaojun, Tsun, Joseph G. S., Fung, Genevieve P. G., Lui, Grace C. Y., Chan, Kathy Y. Y., Chan, Paul K. S., Chan, Renee W. Y.
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 30.01.2023
• Subjects: Antibodies, Neutralizing; Antibody Formation; BNT162 Vaccine - immunology; COVID-19 - prevention & control; Humans; hybrid immunity; Immunity, Mucosal; Immunization, Secondary; Immunoglobulin A; Immunoglobulin G; Immunology; longitudinal study; mRNA vaccine; mRNA Vaccines - immunology; mucosal antibody; Prospective Studies; SARS – CoV – 2; SARS – CoV – 2; longitudinal study; hybrid immunity; mucosal antibody; mRNA vaccine
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2023.1127401

Immunity acquired from natural SARS-CoV-2 infection and vaccine wanes overtime. This longitudinal prospective study compared the effect of a booster vaccine (BNT162b2) in inducing the mucosal (nasal) and serological antibody between Covid-19 recovered patients and healthy unexposed subjects with two dose of mRNA vaccine (vaccine-only group). Eleven recovered patients and eleven gender-and-age matched unexposed subjects who had mRNA vaccines were recruited. The SARS-CoV-2 spike 1 (S1) protein specific IgA, IgG and the ACE2 binding inhibition to the ancestral SARS-CoV-2 and omicron (BA.1) variant receptor binding domain were measured in their nasal epithelial lining fluid and plasma. In the recovered group, the booster expanded the nasal IgA dominancy inherited from natural infection to IgA and IgG. They also had a higher S1-specific nasal and plasma IgA and IgG levels with a better inhibition against the omicron BA.1 variant and ancestral SARS-CoV-2 when compared with vaccine-only subjects. The nasal S1-specific IgA induced by natural infection lasted longer than those induced by vaccines while the plasma antibodies of both groups maintained at a high level for at least 21 weeks after booster. The booster benefited all subjects to obtain neutralizing antibody (NAb) against omicron BA.1 variant in plasma while only the Covid-19 recovered subjects had an extra enrichment in nasal NAb against omicron BA.1 variant.